Distress and quality of life in autologous stem cell transplantation: stepped care.

Distress and quality of life of patients treated with autologous stem cell transplantation following high-dose chemotherapy: outcome of stepped care.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON28586

Enrollment

128

Registered

2009-04-20

Start date

2009-07-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hematological malignancy

Interventions

Protocol stepped care: 1. Step 1: Internet based self-help program ('Alles onder controle': a brief web based intervention for problem-solving which is based on self-examination therapy)

2. Step 2: The following treatment options are available in step 2: individual face-to-face counseling, medication, referral to other services.

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients with hematological malignancy (multiple myeloma, (relapsed) (non-)Hodgkin lymphoma, acute myeloid leukemia, or acute lymphoid leukemia) treated with autologous stem cell transplantation following high-dose chemotherapy; 2. Life expectation > 3 months.

Exclusion criteria

Exclusion criteria: 1. Age 65 years (65 is included); 2. Insufficient command of the Dutch language to complete questionnaires; or, if so: no support by family or professional interpreters; 3. Contra-indication for the stepped care approach; 4. No informed consent.

Design outcomes

Primary

Measure	Time frame
Psychological distress (measured with the HADS) and physical role function (subscale from the EORTC-QLQ-C30).	—

Secondary

Measure	Time frame
Other measures of psychological distress (PHQ-9, STAI-state), other aspects of quality of life (EORTC-QLQ-C30, SF-36), cognitions and coping (DGSS, SPSI-R).	—

Contacts

Public ContactA.M.J. Braamse

A.Braamse@ggzingeest.nl+31 (0)20 7885587

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)